Center-Authored Papers

Filters: Author is Alberts, David S  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
2008
Goodman GE, Alberts DS, Meyskens FL.  2008.  Retinol, vitamins, and cancer prevention: 25 years of learning and relearning.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(34):5495-6.
2010
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
2011
Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF et al..  2011.  Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917.. Cancer prevention research (Philadelphia, Pa.). 4(11):1761-9. Abstract
Anticarcinogenic Agents
Goodman GE, Alberts DS, Meyskens FL.  2008.  Retinol, vitamins, and cancer prevention: 25 years of learning and relearning.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(34):5495-6.
Antineoplastic Agents
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Antineoplastic Combined Chemotherapy Protocols
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Carboplatin
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Center-Authored Paper
Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF et al..  2011.  Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917.. Cancer prevention research (Philadelphia, Pa.). 4(11):1761-9. Abstract
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Clinical Trials as Topic
Goodman GE, Alberts DS, Meyskens FL.  2008.  Retinol, vitamins, and cancer prevention: 25 years of learning and relearning.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(34):5495-6.
Disease-Free Survival
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Doxorubicin
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Drug Hypersensitivity
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Female
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Humans
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Goodman GE, Alberts DS, Meyskens FL.  2008.  Retinol, vitamins, and cancer prevention: 25 years of learning and relearning.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(34):5495-6.
Neoplasm Recurrence, Local
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Neoplasm Staging
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Neoplasms
Goodman GE, Alberts DS, Meyskens FL.  2008.  Retinol, vitamins, and cancer prevention: 25 years of learning and relearning.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(34):5495-6.
October 2011
Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF et al..  2011.  Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917.. Cancer prevention research (Philadelphia, Pa.). 4(11):1761-9. Abstract
Ovarian Neoplasms
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Polyethylene Glycols
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract
Public Health Sciences Division
Goodman GE, Alberts DS, Meyskens FL.  2008.  Retinol, vitamins, and cancer prevention: 25 years of learning and relearning.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 26(34):5495-6.
Marshall JR, Tangen CM, Sakr WA, Wood DP, Berry DL, Klein EA, Lippman SM, Parnes HL, Alberts DS, Jarrard DF et al..  2011.  Phase III Trial of Selenium to Prevent Prostate Cancer in Men with High-grade Prostatic Intraepithelial Neoplasia: SWOG S9917.. Cancer prevention research (Philadelphia, Pa.). 4(11):1761-9. Abstract
Markman M, Moon J, Wilczynski S, Lopez AM, Rowland KM, Michelin DP, Lanzotti VJ, Anderson GL, Alberts DS.  2010.  Single agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trial.. Gynecologic oncology. 116(3):323-5. Abstract